同步放化疗与序贯放化疗对中晚期宫颈癌疗效的对比研究  

A contrastive study on concurrent chemoradiotherapy and sequential chemoradiotherapy for advanced cervical cancer

作　　者：张震[1] 彭红华[1] 张曦[1] 

机构地区：[1]中南大学湘雅三医院肿瘤科,湖南长沙410013

出　　处：《中国医药导报》2011年第14期30-31,共2页China Medical Herald

摘　　要：目的:探讨同步放化疗与序贯放化疗对中晚期宫颈癌的临床疗效。方法:将86例中晚期宫颈癌患者分为同步放化疗组(46例)和序贯放化疗组(40例),比较两组患者临床疗效、生存率及并发症。结果:化疗结束后同步放化疗组与序贯放化疗组患者治疗有效率分别为91.3%、87.5%,差异无统计学意义(P>0.05);同步放化疗组与序贯放化疗组4年生存率分别为84.8%、70.0%,差异有统计学意义(P<0.05);同步放化疗组盆腔复发率和远处转移率分别为4.3%、4.3%,显著低于序贯放化疗组的15.0%、12.5%,差异有统计学意义(P<0.05);两组并发症主要为骨髓抑制及消化道反应,两组均可耐受。结论:与序贯放化疗相比,同步放化疗治疗中晚期宫颈癌可提高患者4年生存率,减少局部复发率及远处转移率,且不良反应可耐受。Objective： To explore the clinical effect of concurrent chemoradiotherapy and sequential chemoradiotherapy for advanced cervical cancer. Methods： 86 cases with advanced cervical cancer were randomly divided into concurrent chemoradiotherapy group （46 cases） and sequential chemoradiotherapy group （40 cases）. The clinical effect, survival rate and complications were analyzed in two group. Results： The local contral were 91.3% and 87.5% in concurrent chemora diotherapy group and sequential chemoradiotherapy group respectively with significant difference （P〈0.05）; the total 4 sur vival rate were 84.8% and 70.0% in the two group with significant difference （P〈0.05）; the pelvic recurrence and distant metastasis were much lower in concurrent chemoradiotherapy group than that of sequential chemoradiotherapy group （P〈 0.05）. Bone marrow inhibition and reaction of digestive tract were the major complications, but the patients could bear the sufferings. Conclusion： Compared with sequential ehemoradiotherapy, concurrent chemoradiotherapy for advanced cervical cancer can improve the total 4 survival rate and lower the pelvic recurrence and distant metastasis with complications toler ated.

关 键 词：中晚期宫颈癌 同步放化疗 序贯放化疗 

分 类 号：R737.33[医药卫生—肿瘤]